老年手术患者术前减药的系统综述
该研究系统检索了EMBASE、CINAHL和PubMed(至2021年1月12日),纳入≥65岁接受择期或急诊手术且进行减药或药物相关干预的老年患者研究,总结术前减药对术后结局的影响。结果显示减药干预实施方式包括老年科医生主导(n=2)、跨学科团队主导(n=8)和药师主导(n=6),结局涉及医疗资源利用、患者结局和药物变化,但异质性大难以比较,总体结果为阳性或中性。结论认为证据较弱,需未来研究关注跨学科方法、与初级保健协调及验证过的减药标准。
要点
- 术前减药干预以跨学科团队主导最常见(n=8),其次为药师主导(n=6)和老年科医生主导(n=2)。
- 减药结局涉及医疗资源利用、患者结局和药物变化,但异质性大难以比较,总体为阳性或中性。
- 证据强度弱,因干预和结局异质性、部分研究纳入非手术病例及低检验效能。
核心结论
- 术前减药对老年手术患者的证据因干预实施和结局异质性、部分研究纳入非手术病例及低检验效能而较弱。
- 总体结果为阳性或中性而非阴性,应让临床医生放心在手术期间对老年人实施减药。
研究设计与样本
- 系统综述,检索EMBASE、CINAHL和PubMed从建库至2021年1月12日。
- 纳入≥65岁接受择期或急诊手术且进行减药或药物相关干预的老年患者研究,场所包括术前门诊至医院术前阶段。
主要发现
- 识别出三种术前减药干预实施方式:老年科医生主导(n=2)、跨学科团队主导(n=8)和药师主导(n=6)。
- 结局涉及医疗资源利用、患者结局和药物变化,但因主题内结局异质性难以比较。
- 总体结果要么阳性要么中性。
关键数值与推荐
- 减药干预实施方式:老年科医生主导(n=2)、跨学科团队主导(n=8)、药师主导(n=6)。
- 未来研究可考虑跨学科方法、从等待手术至出院后与初级保健提供者协调减药、以及易于实施的验证减药标准如STOPP/START。
临床怎么用
- 临床医生可在手术期间对老年人实施减药,因结果呈阳性或中性而非阴性。
- 可考虑跨学科方法进行术前减药。
- 减药努力应从等待手术期协调至出院后,并与初级保健提供者协作。
- 可考虑使用易于实施的验证减药标准如STOPP/START。
局限性
- 干预实施和结局异质性大,结果难以比较。
- 部分研究纳入非手术病例。
- 研究检验效能低,证据强度弱。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To summarize the evidence for preoperative deprescribing and its effect on postoperative outcomes in older adults undergoing surgery. DESIGN: Systematic review. SETTING AND PARTICIPANTS: All available studies. METHODS: We searched EMBASE, Cumulative Index of Nursing and Allied Health (CINAHL), and PubMed from inception to January 12, 2021. Settings included outpatient settings during the waiting period for surgery (ie, preoperative clinic) through to the preoperative period in the hospital. Participants who were older adults, aged ≥65 years, undergoing planned or emergency surgery with deprescribing or medication-related interventions were included for review. RESULTS: We identified 3 different methods of deprescribing intervention delivery during the preoperative period: geriatrician-led (n = 2), interdisciplinary team-led (n = 8), and pharmacist-led (n = 6). Outcomes were related to health care utilization, patient outcomes, and medication changes; however, results were difficult to compare because of heterogeneous outcomes within the topics. Overall, results were either positive or neutral. CONCLUSIONS AND IMPLICATIONS: The evidence for deprescribing during the preoperative period for older adults undergoing surgery is weak because of the heterogeneity of intervention delivery and outcomes, inclusion of nonoperative cases in some studies, and low power. This review highlights the need for future research, which may consider the following: (1) interdisciplinary approach, (2) coordination of deprescribing efforts with primary care provider from the waiting period for surgery up to after hospital discharge, and (3) validated deprescribing criteria such as STOPP/START that is easy to implement. It is important to note that results yielded positive and neutral results, not negative ones, which should reassure clinicians to implement deprescribing for older adults during the surgical period. Additionally, policy initiatives such as integrated electronic medical records or increased reimbursement of deprescribing efforts for primary care providers and/or hospitals should be pursued to prevent adverse postoperative events for this population.
引用
- Lee JW, Li M, Boyd CM, et al. Preoperative Deprescribing for Medical Optimization of Older Adults Undergoing Surgery: A Systematic Review. J Am Med Dir Assoc. 2021. PMID: 34861224. doi:10.1016/j.jamda.2021.11.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。